Dive into the archives.
- Hot off the ECTRIMS Press: Peptimmune Completes Ph 1b Study of PI-2301
Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
CAMBRIDGE, Mass., Aug. 25 /PRNewswire/ — Peptimmune, Inc., a privately held biotechnology company, announced the completion of a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is [...]
- Human Protein May Hold Clues to New MS Treatment
Research into Multiple Sclerosis Raises Hopes of New Treatment
Scientists at the University of Bristol in the West of England have discovered that a protein present in the human body can resist Multiple Sclerosis (MS).
Galanin is a protein which, according to Professor David Wynick, has been recognized for some time as offering protection for all of [...]
- MS Patients Who Smoke Show More Brain Atrophy/Lesions Than MS Nonsmokers
ScienceDaily (Aug. 18, 2009) — Persons with multiple sclerosis who smoked for a little as six months during their lifetime had more destruction of brain tissue and more brain atrophy than MS patients who never smoked, a study by neuroimaging specialists at the University at Buffalo has shown.
Research published in the Aug. 18, 2009, issue [...]
- Generic Betaseron Wins FDA Approval
By Eva von Schaper
Aug. 17 (Bloomberg) — Novartis AG won U.S. Food and Drug Administration approval to sell its Extavia multiple sclerosis treatment, its brand of Bayer AG’s Betaseron.
Extavia, a form of interferon beta-1b, can be used in patients with early and relapsing forms of multiple sclerosis, Basel, Switzerland-based Novartis said in a statement today.
Selling [...]
- Researchers Successfully Reverse MS In Animals
Article Date: 12 Aug 2009 – 1:00 PDT
A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.
MS is an autoimmune disease in [...]
- Elan and Biogen are in a Fight
Elan starts legal action in drug row with Biogen
By Andrew Jack
Published: August 6 2009 22:34 | Last updated: August 6 2009 22:34
Elan has launched legal action to prevent the “irreparable injury” that would be caused by the collapse of its partnership with Biogen Idec over its pivotal multiple sclerosis drug.
The Ireland-based pharmaceuticals company is challenging [...]
- Facet Biotech Announces Daclizumab MS Program to Advance
Aug 03, 2009 16:30 ET
REDWOOD CITY, CA–(Marketwire – August 3, 2009) – Facet Biotech Corporation today announced its decision, along with its partner Biogen Idec, to continue planning for the phase 3 trial of daclizumab high-yield process (DAC HYP) in multiple sclerosis (MS). The company plans to request a Special Protocol Assessment from [...]
